HC Wainwright Estimates Ardelyx’s Q3 Earnings (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX) – HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for Ardelyx in a research report issued to clients and investors on Tuesday, August 5th. HC Wainwright analyst M. Caufield now expects that the biopharmaceutical company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx’s Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.38) EPS and FY2026 earnings at ($0.17) EPS.

ARDX has been the topic of several other reports. Citigroup dropped their target price on Ardelyx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. UBS Group set a $12.00 price objective on Ardelyx in a report on Tuesday. Raymond James Financial reissued an “outperform” rating and issued a $12.00 price objective (up from $11.00) on shares of Ardelyx in a report on Tuesday. Piper Sandler raised their price objective on Ardelyx from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, Wall Street Zen downgraded shares of Ardelyx from a “hold” rating to a “sell” rating in a report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Ardelyx Stock Down 1.2%

Ardelyx stock opened at $5.14 on Thursday. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -22.35 and a beta of 0.68. Ardelyx has a 52 week low of $3.21 and a 52 week high of $7.18. The business’s 50-day moving average price is $4.13 and its 200 day moving average price is $4.64. The company has a quick ratio of 3.81, a current ratio of 4.30 and a debt-to-equity ratio of 1.44.

Ardelyx (NASDAQ:ARDX) last posted its earnings results on Monday, August 4th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.05. The firm had revenue of $97.66 million for the quarter, compared to analyst estimates of $82.69 million. Ardelyx had a negative return on equity of 36.57% and a negative net margin of 14.60%. Ardelyx’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period last year, the company earned ($0.07) earnings per share.

Institutional Investors Weigh In On Ardelyx

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARDX. Vanguard Group Inc. raised its position in Ardelyx by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 14,362,659 shares of the biopharmaceutical company’s stock valued at $72,819,000 after purchasing an additional 767,111 shares during the period. Orion Portfolio Solutions LLC raised its position in Ardelyx by 42.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 16,486 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 4,933 shares during the period. Geode Capital Management LLC raised its position in Ardelyx by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,730 shares of the biopharmaceutical company’s stock valued at $27,941,000 after purchasing an additional 21,988 shares during the period. Invesco Ltd. raised its position in Ardelyx by 9.2% in the fourth quarter. Invesco Ltd. now owns 124,945 shares of the biopharmaceutical company’s stock valued at $633,000 after purchasing an additional 10,514 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in Ardelyx in the fourth quarter valued at $930,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Insider Activity

In related news, insider Laura A. Williams sold 6,421 shares of Ardelyx stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total transaction of $26,197.68. Following the transaction, the insider owned 402,583 shares in the company, valued at approximately $1,642,538.64. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David M. Mott acquired 200,000 shares of Ardelyx stock in a transaction that occurred on Monday, June 16th. The shares were bought at an average price of $3.63 per share, for a total transaction of $726,000.00. Following the transaction, the director owned 2,896,871 shares of the company’s stock, valued at $10,515,641.73. This represents a 7.42% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 500,000 shares of company stock valued at $1,793,000 and have sold 83,477 shares valued at $340,586. 4.80% of the stock is owned by corporate insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.